Christian S. Carl

Christian S. Carl

Auto-generated profile, based on publicly available information

Christian S. Carl

August Krogh Section for Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in Nature
Verified
Journal Article
Closed access
PDF file
VLVeronica L. Li
Veronica L. Li
YHYang He
Yang He
Kevin ContrepoisKevin Contrepois
Kevin Contrepois
HLHailan Liu
Hailan Liu
JKJoon T. Kim
Joon T. Kim
JLJonathan Z. Long
Jonathan Z. Long

17 September 2020 in Cell
Verified
Journal Article
Closed access
ARAnita Reddy
Anita Reddy
LBLuiz H.M. Bozi
Luiz H.M. Bozi
OYOmar K. Yaghi
Omar K. Yaghi
EMEvanna L. Mills
Evanna L. Mills
HXHaopeng Xiao
Haopeng Xiao
ECEdward T. Chouchani
Edward T. Chouchani

1 May 2020 in Molecular Metabolism
Verified
Journal Article
Open access
Andreas FritzenAndreas Fritzen
Andreas Fritzen
JDJoan Domingo-Espín
Joan Domingo-Espín
ALAnnemarie Lundsgaard
Annemarie Lundsgaard
MKMaximilian Kleinert
Maximilian Kleinert
IIIda Israelsen
Ida Israelsen
BKBente Kiens
Bente Kiens
Acute administration of the main protein component of high-density lipoprotein, apolipoprotein A-I (ApoA-1), improves glucose uptake in skeletal muscle. The molecular mechanisms mediating this are not known, but in muscle cell cultures, ApoA-1 failed to increase glucose uptake when infected with a dominant-negative AMP-activated protein kinase (AMPK) virus. We therefore investigated whether AMPK is necessary for ApoA-1-stimulated glucose uptake in intact heart and skeletal muscle in vivo. The effect of injection with recombinant human ApoA-1 (rApoA-1) on glucose tolerance, glucose-stimulated insulin secretion, and glucose uptake into skeletal and heart muscle with and without block of insulin secretion by injection of epinephrine (0.1 mg/kg) and propranolol (5 mg/kg), were investigated in 8 weeks high-fat diet-fed (60E%) wild-type and AMPKα2 kinase-dead mice in the overnight-fasted state. In addition, the effect of rApoA-1 on glucose uptake in isolated skeletal muscle ex vivo was studied. rApoA-1 lowered plasma glucose concentration by 1.7 mmol/l within 3 h (6.1 vs 4.4 mmol/l; p < 0.001). Three hours after rApoA-1 injection, glucose tolerance during a 40-min glucose tolerance test (GTT) was improved compared to control (area under the curve (AUC) reduced by 45%, p < 0.001). This was accompanied by an increased glucose clearance into skeletal (+110%; p < 0.001) and heart muscle (+100%; p < 0.001) and an increase in glucose-stimulated insulin secretion 20 min after glucose injection (+180%; p < 0.001). When insulin secretion was blocked during a GTT, rApoA-1 still enhanced glucose tolerance (AUC lowered by 20% compared to control; p < 0.001) and increased glucose clearance into skeletal (+50%; p < 0.05) and heart muscle (+270%; p < 0.001). These improvements occurred to a similar extent in both wild-type and AMPKα2 kinase-dead mice and thus independently of AMPKα2 activity in skeletal- and heart muscle. Interestingly, rApoA-1 failed to increase glucose uptake in isolated skeletal muscles ex vivo. In conclusion, ApoA-1 stimulates in vivo glucose disposal into skeletal and heart muscle independently of AMPKα2. The observation that ApoA-1 fails to increase glucose uptake in isolated muscle ex vivo suggests that additional systemic effects are required.

1 January 2020 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
ALAnnemarie Lundsgaard
Annemarie Lundsgaard
Andreas FritzenAndreas Fritzen
Andreas Fritzen
TNTrine S. Nicolaisen
Trine S. Nicolaisen
CCChristian S. Carl
Christian S. Carl
KSKim A. Sjøberg
Kim A. Sjøberg
MKMaximilian Kleinert
Maximilian Kleinert
Anne-Marie Lundsgaard, Andreas M. Fritzen, Trine S. Nicolaisen, Christian S. Carl, Kim A. Sjøberg, Steffen H. Raun, Anders B. Klein, Eva Sanchez-Quant, Jakob Langer, Cathrine Ørskov, Christoffer Clemmensen, Matthias H. Tschöp, Erik A. Richter, Bente Kiens, Maximilian Kleinert

2 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAdriana Miranda-Cervantes
Adriana Miranda-Cervantes
Andreas FritzenAndreas Fritzen
Andreas Fritzen
SRSteffen H. Raun
Steffen H. Raun
OHOndřej Hodek
Ondřej Hodek
LMLisbeth Liliendal Valbjørn Møller
Lisbeth Liliendal Valbjørn Møller
MKMaximilian Kleinert
Maximilian Kleinert
Metabolic flexibility in skeletal muscle is essential for maintaining healthy glucose and lipid metabolism, and its dysfunction is closely linked to metabolic diseases. Exercise enhances metabolic flexibility, making it an important tool for discovering mechanisms that promote metabolic health. Here we show that pantothenate kinase 4 (PanK4) is a new conserved exercise target with high abundance in muscle. Muscle-specific deletion of PanK4 impairs fatty acid oxidation which is related to higher intramuscular acetyl-CoA and malonyl-CoA levels. Elevated acetyl-CoA levels persist regardless of feeding state and are associated with whole-body glucose intolerance, reduced insulin-stimulated glucose uptake in glycolytic muscle, and impaired glucose uptake during exercise. Conversely, increasing PanK4 levels in glycolytic muscle lowers acetyl-CoA and enhances glucose uptake. Our findings highlight PanK4 as an important regulator of acetyl-CoA levels, playing a key role in both muscle lipid and glucose metabolism.

31 October 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
JKJonas M. Kristensen
Jonas M. Kristensen
Rasmus KjøbstedRasmus Kjøbsted
Rasmus Kjøbsted
TLTrine J. Larsen
Trine J. Larsen
CCChristian S. Carl
Christian S. Carl
JHJanne R. Hingst
Janne R. Hingst
JWJørgen F. P. Wojtaszewski
Jørgen F. P. Wojtaszewski
In the Greenlandic Inuit population, 4% are homozygous carriers of a genetic nonsense TBC1D4 p.Arg684Ter variant leading to loss of the muscle-specific isoform of TBC1D4 and an approximately tenfold increased risk of type 2 diabetes1. Here we show the metabolic consequences of this variant in four female and four male homozygous carriers and matched controls. An extended glucose tolerance test reveals prolonged hyperglycaemia followed by reactive hypoglycaemia in the carriers. Whole-body glucose disposal is impaired during euglycaemic-hyperinsulinaemic clamp conditions and associates with severe insulin resistance in skeletal muscle only. Notably, a marked reduction in muscle glucose transporter GLUT4 and associated proteins is observed. While metabolic regulation during exercise remains normal, the insulin-sensitizing effect of a single exercise bout is compromised. Thus, loss of the muscle-specific isoform of TBC1D4 causes severe skeletal muscle insulin resistance without baseline hyperinsulinaemia. However, physical activity can ameliorate this condition. These observations offer avenues for personalized interventions and targeted preventive strategies.